U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07874334) titled 'Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis' on Oct. 08.
Brief Summary: A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis.
Study Start Date: Sept. 15
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Multiple Myeloma (RRMM)
Light-Chain Amyloidosis
Intervention:
BIOLOGICAL: GPRC5D CART
The GPRC5D CART is defines as autologous bone marrow derived T-cells transduced with anti-GPRC5D CAR lentiviral vector encoding the chimeric a...